Scisparc files annual report for year ended december 31, 2021 and provides corporate update

Tel aviv, israel, may 02, 2022 (globe newswire) -- scisparc ltd. (nasdaq: sprc), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “company” or “scisparc”), today announced that it has filed its annual report on form 20-f for the fiscal year ended december 31, 2021 with the u.s. securities and exchange commission (the “sec”).
SPRC Ratings Summary
SPRC Quant Ranking